Earnings Call Summary | PAVmed(PAVM.US) Q1 2024 Earnings Conference
Earnings Call Summary | PAVmed(PAVM.US) Q1 2024 Earnings Conference
The following is a summary of the PAVmed Inc. (PAVM) Q1 2024 Earnings Call Transcript:
以下是PAVMed Inc.(PAVM)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
PAVmed concluded Q1 2024 with a cash position of approximately $37.1 million.
The average quarterly burn rate for the past year was $11.7 million.
PAVmed's subsidiary Lucid Diagnostics registered Q1 revenues of around $1 million.
About 4,000 claims worth nearly $10 million in pro forma revenue were submitted for reimbursement.
The non-GAAP loss for the first quarter of $8.6 million represents a sequential improvement of $2 million from the last quarter and a $2.5 million year-over-year improvement.
PavMed在2024年第一季度結束時現金狀況約爲3,710萬美元。
過去一年的平均季度消耗率爲1170萬美元。
PavMed的子公司Lucid Diagnostics的第一季度收入約爲100萬美元。
大約有4,000份索賠已提交報銷,預計收入接近1,000萬美元。
第一季度的非公認會計准則虧損爲860萬美元,比上一季度連續增長200萬美元,同比增長250萬美元。
Business Progress:
業務進展:
A partnership with Ohio State University Comprehensive Cancer Center is underway for a pilot program involving the Veris Cancer Care platform.
PAVmed's Lucid Diagnostics subsidiary is progressing its efforts to secure successful reimbursements for EsoGuard, esophageal DNA test.
The PMX incubator is developed and the company's first target is PortIO.
In 2024, the company plans to continue enhancing the reimbursement process and direct contracting efforts.
Financial options are being explored for the PMX incubator and Veris Health.
Commercial success is largely reliant on pilot success and ability to secure funds for expansion.
The company is targeting partnerships with academic centers and their venture arms.
Fundraising initiatives are ongoing with strong hopes of raising sufficient capital for individual projects like PortIO, EsoCure, and CarpX.
PAVmed plans to operate a recurring revenue service model, providing $1000-$1200 per patient per year, and eyes transition from pilot program to a full commercial relationship for significant revenue growth.
正在與俄亥俄州立大學綜合癌症中心合作開展一項涉及Veris癌症護理平台的試點計劃。
PavMed的Lucid Diagnostics子公司正在努力確保食管DNA測試ESOGuard的成功報銷。
PMX孵化器已經開發完成,該公司的第一個目標是PortIO。
2024年,該公司計劃繼續加強報銷流程和直接簽約工作。
正在爲PMX孵化器和Veris Health探索財務選擇。
商業成功在很大程度上取決於試點成功和獲得擴張資金的能力。
該公司的目標是與學術中心及其風險投資部門建立合作伙伴關係。
籌款活動正在進行中,人們強烈希望爲PortIO、eSocure和CarPx等個人項目籌集足夠的資金。
PAVMed計劃運營經常性收入服務模式,每年爲每位患者提供1000-1200美元,並着眼於從試點計劃過渡到全面的商業關係,以實現顯著的收入增長。
More details: PAVmed IR
更多詳情: PAVMed 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。